AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 204 filers reported holding AMICUS THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,625 | +3037.6% | 340,871 | +760.5% | 0.04% | +1900.0% |
| Q2 2023 | $498 | +13.4% | 39,614 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $439 | -9.3% | 39,614 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $484 | -99.9% | 39,614 | 0.0% | 0.00% | +50.0% |
| Q3 2022 | $414,000 | -2.6% | 39,614 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $425,000 | +13.3% | 39,614 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $375,000 | -18.1% | 39,614 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $458,000 | +21.2% | 39,614 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $378,000 | -1.0% | 39,614 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $382,000 | -2.3% | 39,614 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $391,000 | -57.3% | 39,614 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $915,000 | +45.5% | 39,614 | -11.0% | 0.00% | +33.3% |
| Q3 2020 | $629,000 | -6.4% | 44,535 | 0.0% | 0.00% | -25.0% |
| Q2 2020 | $672,000 | +63.1% | 44,535 | 0.0% | 0.00% | +33.3% |
| Q1 2020 | $412,000 | +52.6% | 44,535 | +60.6% | 0.00% | +50.0% |
| Q4 2019 | $270,000 | +21.6% | 27,732 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $222,000 | -35.8% | 27,732 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $346,000 | -8.2% | 27,732 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $377,000 | +41.7% | 27,732 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $266,000 | -20.6% | 27,732 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $335,000 | -22.6% | 27,732 | 0.0% | 0.00% | -33.3% |
| Q2 2018 | $433,000 | +3.8% | 27,732 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $417,000 | +4.5% | 27,732 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $399,000 | -4.5% | 27,732 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $418,000 | +49.8% | 27,732 | 0.0% | 0.00% | +50.0% |
| Q2 2017 | $279,000 | +40.9% | 27,732 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $198,000 | +43.5% | 27,732 | 0.0% | 0.00% | +100.0% |
| Q4 2016 | $138,000 | -32.7% | 27,732 | 0.0% | 0.00% | -50.0% |
| Q3 2016 | $205,000 | +9.6% | 27,732 | -19.0% | 0.00% | 0.0% |
| Q2 2016 | $187,000 | -35.3% | 34,216 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $289,000 | -28.6% | 34,216 | -18.0% | 0.00% | -33.3% |
| Q4 2015 | $405,000 | +84.9% | 41,721 | +167.1% | 0.00% | +50.0% |
| Q3 2015 | $219,000 | -0.9% | 15,619 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $221,000 | +225.0% | 15,619 | -46.7% | 0.00% | +100.0% |
| Q3 2013 | $68,000 | 0.0% | 29,300 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $68,000 | – | 29,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |